Protection against pneumonic plague following oral immunization with a non-replicating vaccine

Vaccine

Volumn 28, Issue 36, 2010, Pages 5924-5929

  Jones, Abby ^a   Bosio, Catharine ^a   Duffy, Angela ^a   Goodyear, Andrew ^a   Schriefer, Martin ^b   Dow, Steven ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Antibody; Infection; Mucosal; T cells; Yersinia pestis

Indexed keywords

CATIONIC LIPOSOME NUCLEIC ACID COMPLEX; F1 ANTIGEN; PLAGUE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; PLAGUE; PNEUMONIA; PRIORITY JOURNAL; TREATMENT RESPONSE; YERSINIA PESTIS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; IMMUNITY, HUMORAL; LIPOSOMES; MICE; MICE, INBRED C57BL; PLAGUE; PLAGUE VACCINE; SPECIFIC PATHOGEN-FREE ORGANISMS; YERSINIA PESTIS;

EID: 77955556096     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.020     Document Type: Article

References (50)

1. Prentice M.B., Rahalison L. Plague. Lancet 2007, 369(9568 April):1196-1207.
2. Rollins S.E., Rollins S.M., Ryan E.T. Yersinia pestis and the plague. American Journal of Clinical Pathology 2003, 119(Suppl. June):S78-85.
3. Titball R.W., Leary S.E. Plague. British Medical Bulletin 1998, 54(3):625-633.
4. Titball R.W., Williamson E.D. Yersinia pestis (plague) vaccines. Expert Opinion on Biological Therapy 2004, 4(6 June):965-973.
5. Garmory H.S., Griffin K.F., Brown K.A., Titball R.W. Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague. Vaccine 2003, 21(21-22 June):3051-3057.
6. Williamson E.D. Plague vaccine research and development. Journal of Applied Microbiology 2001, 91(4 October):606-608.
7. Titball R.W., Williamson E.D. Vaccination against bubonic and pneumonic plague. Vaccine 2001, 19(30 July):4175-4184.
8. Cornelius C., Quenee L., Anderson D., Schneewind O. Protective immunity against plague. Advances in Experimental Medicine and Biology 2007, 603:415-424.
9. Benner G.E., Andrews G.P., Byrne W.R., Strachan S.D., Sample A.K., Heath D.G., et al. Immune response to Yersinia outer proteins and other Yersinia pestis antigens after experimental plague infection in mice. Infection and Immunity 1999, 67(4 April):1922-1928.
10. Grosfeld H., Cohen S., Bino T., Flashner Y., Ber R., Mamroud E., et al. Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen. Infection and Immunity 2003, 71(1 January):374-383.
11. Leary S.E., Griffin K.F., Garmory H.S., Williamson E.D., Titball R.W. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague. Microbial Pathogenesis 1997, 23(3 September):167-179.
12. Zauberman A., Cohen S., Levy Y., Halperin G., Lazar S., Velan B., et al. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague. Vaccine 2008, 26(13 March):1616-1625.
13. Do Y., Park C.G., Kang Y.S., Park S.H., Lynch R.M., Lee H., et al. Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells. European Journal of Immunology 2008, 38(1 January):20-29.
14. Cornelius C.A., Quenee L.E., Overheim K.A., Koster F., Brasel T.L., Elli D., et al. Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infection and Immunity 2008, 76(12 December):5588-5597.
15. Stacy S., Pasquali A., Sexton V.L., Cantwell A.M., Kraig E., Dube P.H. An age-old paradigm challenged: old baboons generate vigorous humoral immune responses to LcrV, a plague antigen. Journal of Immunology 2008, 181(1 July):109-115.
16. Heath D.G., Anderson G.W., Mauro J.M., Welkos S.L., Andrews G.P., Adamovicz J., et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 1998, 16(11-12 July):1131-1137.
17. Mizel S.B., Graff A.H., Sriranganathan N., Ervin S., Lees C.J., Lively M.O., et al. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clinical Vaccine Immunology 2009, 16(1 January):21-28.
18. Rocke T.E., Smith S., Marinari P., Kreeger J., Enama J.T., Powell B.S. Vaccination with F1-V fusion protein protects black-footed ferrets (Mustela nigripes) against plague upon oral challenge with Yersinia pestis. Journal of Wildlife Diseases 2008, 44(1 January):1-7.
19. Williamson E.D., Vesey P.M., Gillhespy K.J., Eley S.M., Green M., Titball R.W. An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clinical and Experimental Immunology 1999, 116(1 April):107-114.
20. Yamanaka H., Hoyt T., Yang X., Golden S., Bosio C.M., Crist K., et al. A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague. Infection and Immunity 2008, 76(10 October):4564-4573.
21. Huang J., D'Souza A.J., Alarcon J.B., Mikszta J.A., Ford B.M., Ferriter M.S., et al. Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine. Clinical Vaccine Immunology 2009, 16(5 May):719-725.
22. Lutwick L.I., Nierengarten M.B. Vaccines for category a bioterrorism diseases. Expert Opinion on Biological Therapy 2002, 2(8 December):883-893.
23. Reed D.S., Martinez M.J. Respiratory immunity is an important component of protection elicited by subunit vaccination against pneumonic plague. Vaccine 2006, 24(13 March):2283-2289.
24. Eyles J.E., Williamson E.D., Spiers I.D., Stagg A.J., Jones S.M., Alpar H.O. Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits. Journal of Controlled Release 2000, 63(1-2 January):191-200.
25. Honko A.N., Sriranganathan N., Lees C.J., Mizel S.B. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infection and Immunity 2006, 74(2 February):1113-1120.
26. Yang X., Hinnebusch B.J., Trunkle T., Bosio C.M., Suo Z., Tighe M., et al. Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague. Journal of Immunology 2007, 178(2 January):1059-1067.
27. Liu W.T., Hsu H.L., Liang C.C., Chuang C.C., Lin H.C., Liu Y.T. A comparison of immunogenicity and protective immunity against experimental plague by intranasal and/or combined with oral immunization of mice with attenuated Salmonella serovar Typhimurium expressing secreted Yersinia pestis F1 and V antigen. FEMS Immunology and Medical Microbiology 2007, 51(1 October):58-69.
28. Branger C.G., Fetherston J.D., Perry R.D., Curtiss R. Oral vaccination with different antigens from Yersinia pestis KIM delivered by live attenuated Salmonella typhimurium elicits a protective immune response against plague. Advances in Experimental Medicine and Biology 2007, 603:387-399.
29. Taylor V.L., Titball R.W., Oyston P.C. Oral immunization with a dam mutant of Yersinia pseudotuberculosis protects against plague. Microbiology (Reading, England) 2005, 151(Pt 6 June):1919-1926.
30. Blisnick T., Ave P., Huerre M., Carniel E., Demeure C.E. Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain. Infection and Immunity 2008, 76(8 August):3808-3816.
31. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. Journal of Immunology 2006, 176(12 June):7335-7345.
32. Takeda K., Dow S.W., Miyahara N., Kodama T., Koya T., Taube C., et al. Vaccine-induced CD8+ T cell-dependent suppression of airway hyperresponsiveness and inflammation. Journal of Immunology 2009, 183(1 July):181-190.
33. Templeton N.S., Lasic D.D., Frederik P.M., Strey H.H., Roberts D.D., Pavlakis G.N. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nature Biotechnology 1997, 15(7 July):647-652.
34. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007, 25(30 July):5467-5484.
35. Mestecky J., Russell M.W., Elson C.O. Perspectives on mucosal vaccines: is mucosal tolerance a barrier?. Journal of Immunology 2007, 179(9 November):5633-5638.
36. Smiley S.T. Immune defense against pneumonic plague. Immunological Reviews 2008, 225 (October):256-271.
37. Parent M.A., Berggren K.N., Kummer L.W., Wilhelm L.B., Szaba F.M., Mullarky I.K., et al. Cell-mediated protection against pulmonary Yersinia pestis infection. Infection and Immunity 2005, 73(11 November):7304-7310.
38. Parent M.A., Wilhelm L.B., Kummer L.W., Szaba F.M., Mullarky I.K., Smiley S.T. Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection. Infection and Immunity 2006, 74(6 June):3381-3386.
39. O'Hagan D.T., Ott G.S., Van Nest G. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Molecular Medicine Today 1997, 3(2 February):69-75.
40. Simerska P., Moyle P.M., Olive C., Toth I. Oral vaccine delivery-new strategies and technologies. Current Drug Delivery 2009, (August).
41. Silin D.S., Lyubomska O.V., Jirathitikal V., Bourinbaiar A.S. Oral vaccination: where we are?. Expert Opinion on Drug Delivery 2007, 4(4 July):323-340.
42. Lavelle E.C., O'Hagan D.T. Delivery systems and adjuvants for oral vaccines. Expert Opinion on Drug Delivery 2006, 3(6 November):747-762.
43. O'Hagan D.T., McGee J.P., Holmgren J., Mowat A.M., Donachie A.M., Mills K.H., et al. Biodegradable microparticles for oral immunization. Vaccine 1993, 11(2):149-154.
44. O'Hagan D.T., Palin K., Davis S.S., Artursson P., Sjoholm I. Microparticles as potentially orally active immunological adjuvants. Vaccine 1989, 7(5 October):421-424.
45. Calhoun L.N., Kwon Y.M. Salmonella-based plague vaccines for bioterrorism. Journal of Microbiology, Immunology, and Infection=Wei mian yu gan ran za zhi 2006, 39(2 April):92-97.
46. Arlen P.A., Singleton M., Adamovicz J.J., Ding Y., Davoodi-Semiromi A., Daniell H. Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts. Infection and Immunity 2008, 76(8 August):3640-3650.
47. Ramirez K., Capozzo A.V., Lloyd S.A., Sztein M.B., Nataro J.P., Pasetti M.F. Mucosally delivered Salmonella typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost. Journal of Immunology 2009, 182(2 January):1211-1222.
48. Chattopadhyay A., Park S., Delmas G., Suresh R., Senina S., Perlin D.S., et al. Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Vaccine 2008, 26(50 November):6329-6337.
49. Philipovskiy A.V., Smiley S.T. Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection. Infection and Immunity 2007, 75(2 February):878-885.
50. Kummer L.W., Szaba F.M., Parent M.A., Adamovicz J.J., Hill J., Johnson L.L., et al. Antibodies and cytokines independently protect against pneumonic plague. Vaccine 2008, 26(52 December):6901-6907.